Compounds > 1-o-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid
Page last updated: 2024-12-07

1-o-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

You're asking about a specific chemical compound with a rather complex name: **1-O-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid**.

Here's a breakdown of the compound and its potential relevance to research:

**Structure and Components:**

* **Glucopyranuronic acid:** This is a sugar molecule, specifically a derivative of glucose. It plays a role in many biological processes, including the synthesis of glycosaminoglycans, which are important components of connective tissues.
* **Benzoyl group:** This is a group derived from benzoic acid. It's a common functional group in organic chemistry and can be found in many natural products and pharmaceuticals.
* **Aminobenzoyl group:** This is a benzoyl group with an amine (NH2) group attached. It's also a common functional group in pharmaceuticals, often involved in binding to receptors.
* **2,3-dimethylphenyl group:** This is a benzene ring with two methyl groups attached at positions 2 and 3. This group can affect the overall shape and reactivity of the molecule.

**Potential Relevance to Research:**

The specific compound you mentioned, 1-O-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid, doesn't have a widely known or documented use in research. However, given its structure, it could potentially be interesting for the following reasons:

* **Glycosylation:** The glucopyranuronic acid part suggests that this compound might be involved in glycosylation reactions. Glycosylation is the process of attaching sugar molecules to other molecules, which can have significant effects on their properties and functions. This compound could be a potential substrate or inhibitor for glycosylation enzymes.
* **Drug Development:** The presence of the aminobenzoyl group, with its potential for binding to receptors, suggests that this compound might have pharmacological activity. It could be explored as a potential lead compound for the development of new drugs.
* **Biomarkers:** The unique structure of this compound could make it a potential biomarker for certain diseases or conditions. Biomarkers are substances that can be used to indicate the presence or severity of a disease.

**Important Note:** The specific compound you mentioned has not been extensively studied, and its properties and potential applications are currently unknown. To understand its relevance, you would need to consult specialized literature and research databases.

**To investigate further:**

* **Chemical databases:** Databases like PubChem (pubchem.ncbi.nlm.nih.gov) and ChemSpider (www.chemspider.com) can be helpful to see if there is any available information about this compound.
* **Scientific literature:** Search online scientific databases (PubMed, Google Scholar) using keywords like glucopyranuronic acid, aminobenzoyl, and drug development to find relevant research articles.

Remember, it's always best to consult with experts in relevant fields for a deeper understanding of specific compounds and their potential applications.

1-O-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid: a mefenamic acid metabolite from urine; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128135
CHEMBL ID3527501
MeSH IDM0223810

Synonyms (21)

Synonym
mefenamic acid glucuronide
(2s,3s,4s,5r,6s)-6-[2-(2,3-dimethylanilino)benzoyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
beta-d-glucopyranuronic acid, 1-(2-((2,3-dimethylphenyl)amino)benzoate)
mefenamic acid 1-o-acylglucuronide
1-o-(2-(2,3-dimethylphenyl)aminobenzoyl)glucopyranuronic acid
102623-18-7
unii-ox5h10g1rg
ox5h10g1rg ,
mefenamic acyl-beta-d-glucuronide
.beta.-d-glucopyranuronic acid, 1-(2-((2,3-dimethylphenyl)amino)benzoate)
mefenamic acyl-.beta.-d-glucuronide
CHEMBL3527501
J-000742
mefenamic acyl-?-d-glucuronide
mefenamic acyl-beta-d glucuronide
beta-d-glucopyranuronic acid, 1-[2-[(2,3-dimethylphenyl)amino]benzoate]
Q27285900
1-o-[2-(2,3-dimethylanilino)benzoyl]hexopyranuronic acid
DTXSID90907958
1-[2-[(2,3-dimethylphenyl)amino]benzoate] beta-d-glucopyranuronic acid
mefenamic acyl- beta -d-glucuronide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1222970Half life in rat hepatocytes at 1 uM2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222965Drug level in cryopreserved human hepatocytes treated with 100 uM MFA at 60 mins incubation2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222972Drug level in rat hepatocytes treated with at 100 uM MFA by LC-MS/MS analysis in presence of 1000 uM (-)-borneol (Rvb = 619 +/-158)2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222960Drug level in rat hepatocytes treated with 100 uM MFA after 60 mins2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222984Half life in potassium phosphate buffer at 1 uM at pH 7.4 at 37 degC2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222967Drug level in rat hepatocytes treated with 500 uM MFA by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222964Drug level in cryopreserved human hepatocytes treated with 100 uM MFA at 10 mins incubation2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222953Retention time in rat hepatocytes treated with 100 uM MFA by positive ion LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222969Drug level in rat hepatocytes treated with 62.5 uM MFA by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222986Drug level in Sprague-Dawley rat bile treated with 100 mg/kg, ip MFA after 6 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
AID1222973Drug level in rat hepatocytes treated with at 100 uM MFA by LC-MS/MS analysis in presence of 1000 uM Lauric acid (Rvb = 619 +/-158)2012Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8
Metabolic activation of mefenamic acid leading to mefenamyl-S-acyl-glutathione adduct formation in vitro and in vivo in rat.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (33.33)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.92 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycerol
Moon: The natural satellite of the planet Earth. It includes the lunar cycles or phases, the lunar month, lunar landscapes, geography, and soil.		2.0510alditol;
triol		algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent
phenylacetic acid
phenylacetic acid : A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group.		2.0710benzenes;
monocarboxylic acid;
phenylacetic acids		allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		2.4620amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
mefenamic acid
Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.		3.2860aminobenzoic acid;
secondary amino compound		analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
tolmetin
Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.		2.0510aromatic ketone;
monocarboxylic acid;
pyrroles		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		2.0810adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.0810acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
uridine diphosphate glucuronic acid
Uridine Diphosphate Glucuronic Acid: A nucleoside diphosphate sugar which serves as a source of glucuronic acid for polysaccharide biosynthesis. It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.. UDP-alpha-D-glucuronic acid : A UDP-sugar having alpha-D-glucuronic acid as the sugar component.		2.0510UDP-D-glucuronic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
benoxaprofen
benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.		2.05101,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes		antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist
ibuprofen, (r)-isomer
[no description available]		2.0710ibuprofen
benoxaprofen glucuronide
benoxaprofen glucuronide: metabolite of benoxaprofen; structure given in first source		2.0510
tolmetin glucuronide
tolmetin glucuronide: structure given in first source; metabolite of tolmetin; has been correlated with irreversible binding of the drug to blood proteins		2.0510glucosiduronic acid
naproxen
Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.		2.0510methoxynaphthalene;
monocarboxylic acid		antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
naproxen glucuronide
naproxen glucuronide: structure in first source		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials